Given that the current first- or second-line treatment for patients with stage I–IV pancreatic cancer is Gem plus Ptx, we sought to assess the effect of a PRMT5 pharmacologic inhibitor in combination with Gem plus Ptx. The gene discussed is PRMT5; the disease is pancreatic neoplasm.